A Study of the Safety and Efficacy of the VytronUS Low-Intensity Collimated Ultrasound Ablation System

NCT ID: NCT01900678

Last Updated: 2015-06-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-06-30

Study Completion Date

2015-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this investigation is to evaluate whether pulmonary vein isolation using the VytronUS ablation system is safe and effective acutely and at 3 months.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Paroxysmal Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

VytronUS Ablation System

Treatment with the VytronUS Ablation System.

Group Type EXPERIMENTAL

VytronUS Ablation System

Intervention Type DEVICE

Pulmonary vein isolation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VytronUS Ablation System

Pulmonary vein isolation.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 to 70 years old.
* Recurrent symptomatic paroxysmal atrial fibrillation refractory to at least one antiarrhythmic drug.

Exclusion Criteria

* Prior pulmonary vein isolation
* Presence of intracardiac thrombus
* Indication of inaccessible pulmonary or cardiac anatomy
* Myocardial infarction, PCI, or cardiac surgery in prior three months
* Moderate to severe valvular disease or prior valve replacement
* NYHA Class IV
* LVEF \< 40%
* Previous stroke or TIA
* Serum creatinine \> 2.5mg/dL or allergy to intravenous contrast agents
* Existing bleeding diathesis or history of complications with anticoagulation therapy
* Women who are nursing, pregnant, or trying to become pregnant
* Subjects unwilling or unable to provide consent
* Participation in a drug or device trial that would prevent completion of required study procedures
* Active implantable devices
* Major organ system disease
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

VytronUS, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Petr Neuzil, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Na Homolce Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Na Homolce Hospital

Prague, , Czechia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Czechia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CIV-13-04-010581

Identifier Type: REGISTRY

Identifier Source: secondary_id

VLIC-USA

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.